Last reviewed · How we verify
[14C]D-0316 suspension
[14C]D-0316 suspension is a Small molecule drug developed by Betta Pharmaceuticals Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | [14C]D-0316 suspension |
|---|---|
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [14C]D-0316 suspension CI brief — competitive landscape report
- [14C]D-0316 suspension updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about [14C]D-0316 suspension
What is [14C]D-0316 suspension?
[14C]D-0316 suspension is a Small molecule drug developed by Betta Pharmaceuticals Co., Ltd..
Who makes [14C]D-0316 suspension?
[14C]D-0316 suspension is developed by Betta Pharmaceuticals Co., Ltd. (see full Betta Pharmaceuticals Co., Ltd. pipeline at /company/betta-pharmaceuticals-co-ltd).
What development phase is [14C]D-0316 suspension in?
[14C]D-0316 suspension is in Phase 1.
Related
- Manufacturer: Betta Pharmaceuticals Co., Ltd. — full pipeline
- Compare: [14C]D-0316 suspension vs similar drugs
- Pricing: [14C]D-0316 suspension cost, discount & access